2021
DOI: 10.1016/j.amjms.2020.06.021
|View full text |Cite
|
Sign up to set email alerts
|

Hyperkalemia and Hypertension Post Organ Transplantation – A Management Challenge

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
3

Relationship

0
3

Authors

Journals

citations
Cited by 3 publications
(1 citation statement)
references
References 34 publications
0
1
0
Order By: Relevance
“…However, fludrocortisone may be used if there are no other effective ways to prevent fatal, severe hyperkalemia. The use of fludrocortisone as a potassium-lowering agent has been reported in hemodialysis patients 11 12 13 14) and organ transplant recipients receiving calcineurin inhibitors 15 16 17 18 19) , but there has been little data regarding the use of fludrocortisone for hyperkalemia control in patients with CKD who are not yet on dialysis.…”
Section: Introductionmentioning
confidence: 99%
“…However, fludrocortisone may be used if there are no other effective ways to prevent fatal, severe hyperkalemia. The use of fludrocortisone as a potassium-lowering agent has been reported in hemodialysis patients 11 12 13 14) and organ transplant recipients receiving calcineurin inhibitors 15 16 17 18 19) , but there has been little data regarding the use of fludrocortisone for hyperkalemia control in patients with CKD who are not yet on dialysis.…”
Section: Introductionmentioning
confidence: 99%